Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exicure, Inc.
  6. News
  7. Summary
    XCUR   US30205M1018

EXICURE, INC.

(XCUR)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 05/25 11:51:02 am
0.117 USD   +0.09%
05/20Top Premarket Gainers
MT
05/19INSIDER BUY : Exicure
MT
05/17Exicure, Inc. - Reports First Quarter 2022 Financial Results and Corporate Progress
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about EXICURE, INC.
05/19INSIDER BUY : Exicure
MT
05/17Exicure, Inc. - Reports First Quarter 2022 Financial Results and Corporate Progress
AQ
05/17Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
BU
05/16Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/16Earnings Flash (XCUR) EXICURE Reports Q1 Revenue $2.57M
MT
05/16Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
BU
05/11Thinking about buying stock in Exicure, Vroom, Redbox, Amyris, or Plug Power?
PR
05/11Exicure to Sell $5 Million of Common Stock in Private Placement at Premium
MT
05/10Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Pr..
BU
05/09Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Confere..
BU
05/09Exicure, Inc. announced that it expects to receive $5.040289 million in funding from Ab..
CI
03/29Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neu..
MT
03/28Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
AQ
03/25EXICURE : Reports Full Year 2021 Financial Results and Corporate Progress - Form 8-K
PU
03/25Exicure Loss Widens Last Year, Sees Enough Funds Through Q4
MT
More most relevant news
All news about EXICURE, INC.
05/20Top Premarket Gainers
MT
05/19INSIDER BUY : Exicure
MT
05/17Exicure, Inc. - Reports First Quarter 2022 Financial Results and Corporate Progress
AQ
05/17Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
BU
05/16EXICURE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/16Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/16Earnings Flash (XCUR) EXICURE Reports Q1 Revenue $2.57M
MT
05/16Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
BU
05/13EXICURE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
05/11Thinking about buying stock in Exicure, Vroom, Redbox, Amyris, or Plug Power?
PR
More news
News in other languages on EXICURE, INC.
05/19ACHAT D'INITIÉS : Exicure
05/16Exicure, Inc. annonce ses résultats pour le premier trimestre se terminant le 31 mars 2..
05/16Earnings Flash (XCUR) EXICURE annonce un chiffre d'affaires de 2,57 millions de dollars..
05/11MISE À JOUR SECTORIELLE : Les actions du secteur de la santé sont en baisse avant la cloch..
03/25La perte d'Exicure s'est creusée l'année dernière, mais elle dispose de suffisamment de..
03/25Exicure, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre 2..
03/25Exicure, Inc. Le vérificateur remet en question la continuité de l'exploitation.
02/04Le président-directeur général, le président du conseil d'administration et d'autres me..
02/04Exicure, Inc. annonce un changement de chef de la direction, à compter du 4 février 202..
02/04Exicure, Inc. annonce des changements au niveau de la direction, du conseil d'administr..
More news
Analyst Recommendations on EXICURE, INC.
03/29Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neu..
MT
2021Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepre..
MT
2021Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clini..
MT
2021EXICURE : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Ratin..
MT
2020EXICURE : BMO Capital Starts Exicure at Outperform With $6 Price Target
MT
More recommendations
Press releases
05/17Exicure, Inc. - Reports First Quarter 2022 Financial Results and Corporate Progress
AQ
05/17Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
BU
05/16EXICURE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/16Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
BU
05/13EXICURE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
More press releases
Upcoming event on EXICURE, INC.
05/24/22H.C. Wainwright Global Life Sciences Investment Conference
Upcoming sector events
07/27/22VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
07/27/22GILEAD SCIENCES, INC. : Interim 2022 Earnings Release (Projected)
08/04/22REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22BIONTECH SE : Interim 2022 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs